CoChat
Sign Up
Cited by 84Liver physiology and pathologyCancer-related Molecular PathwaysHepatocellular Carcinoma Treatment and Prognosis

c-MYC—Making Liver Sick: Role of c-MYC in Hepatic Cell Function, Homeostasis and Disease

Open access
Zheng, Kang, Cubero, Francisco, Nevzorova, Yulia·2017·Genes
DOI 10.3390/genes8040123PMC PMC5406870
Open this paper in CoChat — free accountOpen PDF

Abstract

Over 35 years ago, c-MYC, a highly pleiotropic transcription factor that regulates hepatic cell function, was identified. In recent years, a considerable increment in the number of publications has significantly shifted the way that the c-MYC function is perceived. Overexpression of c-MYC alters a wide range of roles including cell proliferation, growth, metabolism, DNA replication, cell cycle progression, cell adhesion and differentiation. The purpose of this review is to broaden the understanding of the general functions of c-MYC, to focus on c-MYC-driven pathogenesis in the liver, explain its mode of action under basal conditions and during disease, and discuss efforts to target c-MYC as a plausible therapy for liver disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/genes8040123

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The CAR-driven c-Myc-Foxm1 axis has been implicated in promoting hepatocyte proliferation and regeneration in rodents.

    “Although the CAR-driven c-Myc–Foxm1 axis has been implicated in promoting hepatocyte proliferation and regeneration in rodents,43,44”

    From Constitutive Androstane Receptor Regulates Bile Acid Homeostasis and Metabolism During Liver Regeneration (2026) · cites this paper as [43]

    Section 3, “Deconstructing c-MYC: Transgenic Models” (page unavailable), reports increased liver regeneration and faster recovery after partial hepatectomy in c-MYC transgenic mice, supporting the rodent proliferation-and-regeneration aspect. The passages found do not link those effects to CAR or Foxm1, so they do not establish the claimed CAR-driven c-Myc–Foxm1 axis. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 132

  1. [1]Whitfield J.R. Soucek L. Tumor microenvironment: Becoming sick of myc Cell. Mol. Life Sci. 2012 69 931 934 10.1007/s00018-011-0860-x 22033838 PMC3285755 · DOI
  2. [2]Meyer N. Penn L.Z. Reflecting on 25 years with myc Nat. Rev. Cancer 2008 8 976 990 10.1038/nrc2231 19029958 · DOI · Paper page
  3. [3]Miller D.M. Thomas S.D. Islam A. Muench D. Sedoris K. C-myc and cancer metabolism Clin. Cancer Res. 2012 18 5546 5553 10.1158/1078-0432.CCR-12-0977 23071356 PMC3505847 · DOI
  4. [4]Bishop J.M. Retroviruses and cancer genes Adv. Cancer Res. 1982 37 1 32 6763842
  5. [5]Bister K. Jansen H.W. Oncogenes in retroviruses and cells: Biochemistry and molecular genetics Adv. Cancer Res. 1986 47 99 188 3022566
  6. [6]Dang C.V. C-myc target genes involved in cell growth, apoptosis, and metabolism Mol. Cell. Biol. 1999 19 1 11 10.1128/MCB.19.1.1 9858526 PMC83860 · DOI
  7. [7]Duesberg P.H. Vogt P.K. Avian acute leukemia viruses mc29 and mh2 share specific rna sequences: Evidence for a second class of transforming genes Proc. Natl. Acad. Sci. USA 1979 76 1633 1637 10.1073/pnas.76.4.1633 221900 PMC383444 · DOI
  8. [8]Hu S.S. Lai M.M. Vogt P.K. Genome of avian myelocytomatosis virus mc29: Analysis by heteroduplex mapping Proc. Natl. Acad. Sci. USA 1979 76 1265 1268 10.1073/pnas.76.3.1265 86989 PMC383231 · DOI
  9. [9]Sheiness D. Bishop J.M. DNA and rna from uninfected vertebrate cells contain nucleotide sequences related to the putative transforming gene of avian myelocytomatosis virus J. Virol. 1979 31 514 521 225569 PMC353474
  10. [10]Dalla-Favera R. Bregni M. Erikson J. Patterson D. Gallo R.C. Croce C.M. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in burkitt lymphoma cells Proc. Natl. Acad. Sci. USA 1982 79 7824 7827 10.1073/pnas.79.24.7824 6961453 PMC347441 · DOI
  11. [11]Taub R. Kirsch I. Morton C. Lenoir G. Swan D. Tronick S. Aaronson S. Leder P. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human burkitt lymphoma and murine plasmacytoma cells Proc. Natl. Acad. Sci. USA 1982 79 7837 7841 10.1073/pnas.79.24.7837 6818551 PMC347444 · DOI
  12. [12]Soucek L. Evan G. Myc-is this the oncogene from hell? Cancer Cell 2002 1 406 408 10.1016/S1535-6108(02)00077-6 12124167 · DOI
  13. [13]Thompson N.L. Mead J.E. Braun L. Goyette M. Shank P.R. Fausto N. Sequential protooncogene expression during rat liver regeneration Cancer Res. 1986 46 3111 3117 3516391
  14. [14]Fausto N. Mead J.E. Braun L. Thompson N.L. Panzica M. Goyette M. Bell G.I. Shank P.R. Proto-oncogene expression and growth factors during liver regeneration Symp. Fundam. Cancer Res. 1986 39 69 86 3321311
  15. [15]Sanders J.A. Gruppuso P.A. Nucleolar localization of hepatic c-myc: A potential mechanism for c-myc regulation Biochim. Biophys. Acta 2005 1743 141 150 10.1016/j.bbamcr.2004.09.009 15777849 · DOI
  16. [16]Davis A.C. Wims M. Spotts G.D. Hann S.R. Bradley A. A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice Genes Dev. 1993 7 671 682 10.1101/gad.7.4.671 8458579 · DOI
  17. [18]Sanders J.A. Schorl C. Patel A. Sedivy J.M. Gruppuso P.A. Postnatal liver growth and regeneration are independent of c-myc in a mouse model of conditional hepatic c-myc deletion BMC Physiol. 2012 12 1 10.1186/1472-6793-12-1 22397685 PMC3353165 · DOI
  18. [19]Li F. Xiang Y. Potter J. Dinavahi R. Dang C.V. Lee L.A. Conditional deletion of c-myc does not impair liver regeneration Cancer Res. 2006 66 5608 5612 10.1158/0008-5472.CAN-05-4242 16740696 · DOI
  19. [20]He C. Hu H. Braren R. Fong S.Y. Trumpp A. Carlson T.R. Wang R.A. C-myc in the hematopoietic lineage is crucial for its angiogenic function in the mouse embryo Development 2008 135 2467 2477 10.1242/dev.020131 18550710 PMC2597486 · DOI
  20. [21]Muakkassah-Kelly S.F. Jans D.A. Lydon N. Bieri F. Waechter F. Bentley P. Staubli W. Electroporation of cultured adult rat hepatocytes with the c-myc gene potentiates DNA synthesis in response to epidermal growth factor Exp. Cell Res. 1988 178 296 306 10.1016/0014-4827(88)90400-4 3049121 · DOI
  21. [22]Factor V.M. Jensen M.R. Thorgeirsson S.S. Coexpression of c-myc and transforming growth factor alfa in the liver promotes early replicative senescence and diminishes regenerative capacity after partial hepatectomy in transgenic mice Hepatology 1997 26 1434 1443 10.1002/hep.510260610 9397983 · DOI
  22. [23]Murakami H. Sanderson N.D. Nagy P. Marino P.A. Merlino G. Thorgeirsson S.S. Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: Interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis Cancer Res. 1993 53 1719 1723 8467484
  23. [24]Freimuth J. Gassler N. Moro N. Gunther R.W. Trautwein C. Liedtke C. Krombach G.A. Application of magnetic resonance imaging in transgenic and chemical mouse models of hepatocellular carcinoma Mol. Cancer 2010 9 94 10.1186/1476-4598-9-94 20429921 PMC2868806 · DOI
  24. [25]Thorgeirsson S.S. Santoni-Rugiu E. Transgenic mouse models in carcinogenesis: Interaction of c-myc with transforming growth factor alpha and hepatocyte growth factor in hepatocarcinogenesis Br. J. Clin. Pharmacol. 1996 42 43 52 10.1046/j.1365-2125.1996.03748.x 8807143 PMC2042635 · DOI
  25. [26]Ohgaki H. Sanderson N.D. Ton P. Thorgeirsson S.S. Molecular analyses of liver tumors in c-myc transgenic mice and c-myc and tgf-alpha double transgenic mice Cancer Lett. 1996 106 43 49 10.1016/0304-3835(96)04299-1 8827045 · DOI
  26. [27]Conner E.A. Lemmer E.R. Sanchez A. Factor V.M. Thorgeirsson S.S. E2f1 blocks and c-myc accelerates hepatic ploidy in transgenic mouse models Biochem. Biophys. Res. Commun. 2003 302 114 120 10.1016/S0006-291X(03)00125-6 12593856 · DOI
  27. [28]Klocke R. Bartels T. Jennings G. Brand K. Halter R. Strauss M. Paul D. Lack of p53 accelerates hepatocarcinogenesis in transgenic mice constitutively overexpressing c-myc in the liver FASEB J. 2001 15 1404 1406 10.1096/fj.00-0487fje 11387238 · DOI
  28. [29]Beer S. Komatsubara K. Bellovin D.I. Kurobe M. Sylvester K. Felsher D.W. Hepatotoxin-induced changes in the adult murine liver promote myc-induced tumorigenesis PLoS ONE 2008 3 e2493 10.1371/journal.pone.0002493 18560566 PMC2423614 · DOI
  29. [30]Terradillos O. Billet O. Renard C.A. Levy R. Molina T. Briand P. Buendia M.A. The hepatitis b virus x gene potentiates c-myc-induced liver oncogenesis in transgenic mice Oncogene 1997 14 395 404 10.1038/sj.onc.1200850 9053836 · DOI
  30. [31]Kim S. Li Q. Dang C.V. Lee L.A. Induction of ribosomal genes and hepatocyte hypertrophy by adenovirus-mediated expression of c-myc in vivo Proc. Natl. Acad. Sci. USA 2000 97 11198 11202 10.1073/pnas.200372597 11005843 PMC17177 · DOI
  31. [33]Sandgren E.P. Quaife C.J. Pinkert C.A. Palmiter R.D. Brinster R.L. Oncogene-induced liver neoplasia in transgenic mice Oncogene 1989 4 715 724 2543942
  32. [34]Hermeking H. Eick D. Mediation of c-myc-induced apoptosis by p53 Science 1994 265 2091 2093 10.1126/science.8091232 8091232 · DOI
  33. [35]Lindstrom M.S. Wiman K.G. Myc and e2f1 induce p53 through p14arf-independent mechanisms in human fibroblasts Oncogene 2003 22 4993 5005 10.1038/sj.onc.1206659 12902982 · DOI
  34. [36]Heindryckx F. Colle I. Van Vlierberghe H. Experimental mouse models for hepatocellular carcinoma research Int. J. Exp. Pathol. 2009 90 367 386 10.1111/j.1365-2613.2009.00656.x 19659896 PMC2741148 · DOI
  35. [37]Tonjes R.R. Lohler J. O’Sullivan J.F. Kay G.F. Schmidt G.H. Dalemans W. Pavirani A. Paul D. Autocrine mitogen igegf cooperates with c-myc or with the hcs locus during hepatocarcinogenesis in transgenic mice Oncogene 1995 10 765 768 7862454
  36. [38]Ladu S. Calvisi D.F. Conner E.A. Farina M. Factor V.M. Thorgeirsson S.S. E2f1 inhibits c-myc-driven apoptosis via pik3ca/akt/mtor and cox-2 in a mouse model of human liver cancer Gastroenterology 2008 135 1322 1332 10.1053/j.gastro.2008.07.012 18722373 PMC2614075 · DOI
  37. [39]Li Z. Van Calcar S. Qu C. Cavenee W.K. Zhang M.Q. Ren B. A global transcriptional regulatory role for c-myc in burkitt’s lymphoma cells Proc. Natl. Acad. Sci. USA 2003 100 8164 8169 10.1073/pnas.1332764100 12808131 PMC166200 · DOI
  38. [40]Pickering M.T. Stadler B.M. Kowalik T.F. Mir-17 and mir-20a temper an e2f1-induced g1 checkpoint to regulate cell cycle progression Oncogene 2009 28 140 145 10.1038/onc.2008.372 18836483 PMC2768269 · DOI
  39. [41]Zeller K.I. Zhao X. Lee C.W. Chiu K.P. Yao F. Yustein J.T. Ooi H.S. Orlov Y.L. Shahab A. Yong H.C. Global mapping of c-myc binding sites and target gene networks in human b cells Proc. Natl. Acad. Sci. USA 2006 103 17834 17839 10.1073/pnas.0604129103 17093053 PMC1635161 · DOI
  40. [42]Santoni-Rugiu E. Duro D. Farkas T. Mathiasen I.S. Jaattela M. Bartek J. Lukas J. E2f activity is essential for survival of myc-overexpressing human cancer cells Oncogene 2002 21 6498 6509 10.1038/sj.onc.1205828 12226753 · DOI
  41. [43]Leone G. Sears R. Huang E. Rempel R. Nuckolls F. Park C.H. Giangrande P. Wu L. Saavedra H.I. Field S.J. Myc requires distinct e2f activities to induce s phase and apoptosis Mol. Cell 2001 8 105 113 10.1016/S1097-2765(01)00275-1 11511364 · DOI
  42. [44]Akita H. Marquardt J.U. Durkin M.E. Kitade M. Seo D. Conner E.A. Andersen J.B. Factor V.M. Thorgeirsson S.S. Myc activates stem-like cell potential in hepatocarcinoma by a p53-dependent mechanism Cancer Res. 2014 74 5903 5913 10.1158/0008-5472.CAN-14-0527 25189530 PMC4199878 · DOI
  43. [45]Kim J. Woo A.J. Chu J. Snow J.W. Fujiwara Y. Kim C.G. Cantor A.B. Orkin S.H. A myc network accounts for similarities between embryonic stem and cancer cell transcription programs Cell 2010 143 313 324 10.1016/j.cell.2010.09.010 20946988 PMC3018841 · DOI
  44. [46]Vafa O. Wade M. Kern S. Beeche M. Pandita T.K. Hampton G.M. Wahl G.M. C-myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: A mechanism for oncogene-induced genetic instability Mol. Cell 2002 9 1031 1044 10.1016/S1097-2765(02)00520-8 12049739 · DOI · Paper page
  45. [47]Lee J.S. Chu I.S. Mikaelyan A. Calvisi D.F. Heo J. Reddy J.K. Thorgeirsson S.S. Application of comparative functional genomics to identify best-fit mouse models to study human cancer Nat. Genet. 2004 36 1306 1311 10.1038/ng1481 15565109 · DOI
  46. [48]Li Y. Casey S.C. Felsher D.W. Inactivation of myc reverses tumorigenesis J. Intern. Med. 2014 276 52 60 10.1111/joim.12237 24645771 PMC4065197 · DOI
  47. [49]Nesbit C.E. Tersak J.M. Prochownik E.V. Myc oncogenes and human neoplastic disease Oncogene 1999 18 3004 3016 10.1038/sj.onc.1202746 10378696 · DOI
  48. [50]Peng S.Y. Lai P.L. Hsu H.C. Amplification of the c-myc gene in human hepatocellular carcinoma: Biologic significance J. Formos. Med. Assoc. 1993 92 866 870 7511953
  49. [51]Schlaeger C. Longerich T. Schiller C. Bewerunge P. Mehrabi A. Toedt G. Kleeff J. Ehemann V. Eils R. Lichter P. Etiology-dependent molecular mechanisms in human hepatocarcinogenesis Hepatology 2008 47 511 520 10.1002/hep.22033 18161050 · DOI
  50. [52]Poon T.C. Wong N. Lai P.B. Rattray M. Johnson P.J. Sung J.J. A tumor progression model for hepatocellular carcinoma: Bioinformatic analysis of genomic data Gastroenterology 2006 131 1262 1270 10.1053/j.gastro.2006.08.014 17030195 · DOI
  51. [53]Kawate S. Fukusato T. Ohwada S. Watanuki A. Morishita Y. Amplification of c-myc in hepatocellular carcinoma: Correlation with clinicopathologic features, proliferative activity and p53 overexpression Oncology 1999 57 157 163 10.1159/000012024 10461064 · DOI
  52. [54]Lin C.P. Liu C.R. Lee C.N. Chan T.S. Liu H.E. Targeting c-myc as a novel approach for hepatocellular carcinoma World J. Hepatol. 2010 2 16 20 21160952 PMC2999263
  53. [55]Wang Y. Wu M.C. Sham J.S. Zhang W. Wu W.Q. Guan X.Y. Prognostic significance of c-myc and aib1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray Cancer 2002 95 2346 2352 10.1002/cncr.10963 12436441 · DOI
  54. [56]Kaposi-Novak P. Libbrecht L. Woo H.G. Lee Y.H. Sears N.C. Coulouarn C. Conner E.A. Factor V.M. Roskams T. Thorgeirsson S.S. Central role of c-myc during malignant conversion in human hepatocarcinogenesis Cancer Res. 2009 69 2775 2782 10.1158/0008-5472.CAN-08-3357 19276364 PMC2680077 · DOI
  55. [57]Zondervan P.E. Wink J. Alers J.C. JN I.J. Schalm S.W. de Man R.A. van Dekken H. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: Analysis of 26 carcinomas and 12 concurrent dysplasias J. Pathol. 2000 192 207 215 10.1002/1096-9896(2000)9999:9999<::AID-PATH690>3.0.CO;2-# 11004697 · DOI
  56. [58]Simile M.M. De Miglio M.R. Muroni M.R. Frau M. Asara G. Serra S. Muntoni M.D. Seddaiu M.A. Daino L. Feo F. Down-regulation of c-myc and cyclin d1 genes by antisense oligodeoxy nucleotides inhibits the expression of e2f1 and in vitro growth of hepg2 and morris 5123 liver cancer cells Carcinogenesis 2004 25 333 341 10.1093/carcin/bgh014 14604889 · DOI
  57. [59]Wu C.H. van Riggelen J. Yetil A. Fan A.C. Bachireddy P. Felsher D.W. Cellular senescence is an important mechanism of tumor regression upon c-myc inactivation Proc. Natl. Acad. Sci. USA 2007 104 13028 13033 10.1073/pnas.0701953104 17664422 PMC1941831 · DOI
  58. [60]Qu A. Jiang C. Cai Y. Kim J.H. Tanaka N. Ward J.M. Shah Y.M. Gonzalez F.J. Role of myc in hepatocellular proliferation and hepatocarcinogenesis J. Hepatol. 2014 60 331 338 10.1016/j.jhep.2013.09.024 24096051 PMC3909877 · DOI
  59. [61]Weinstein I.B. Cancer. Addiction to oncogenes—The achilles heal of cancer Science 2002 297 63 64 10.1126/science.1073096 12098689 · DOI
  60. [62]Felsher D.W. Bishop J.M. Transient excess of myc activity can elicit genomic instability and tumorigenesis Proc. Natl. Acad. Sci. USA 1999 96 3940 3944 10.1073/pnas.96.7.3940 10097142 PMC22399 · DOI
  61. [63]Karlsson A. Deb-Basu D. Cherry A. Turner S. Ford J. Felsher D.W. Defective double-strand DNA break repair and chromosomal translocations by myc overexpression Proc. Natl. Acad. Sci. USA 2003 100 9974 9979 10.1073/pnas.1732638100 12909717 PMC187906 · DOI
  62. [64]Neiman P.E. Kimmel R. Icreverzi A. Elsaesser K. Bowers S.J. Burnside J. Delrow J. Genomic instability during myc-induced lymphomagenesis in the bursa of fabricius Oncogene 2006 25 6325 6335 10.1038/sj.onc.1209646 16652139 · DOI
  63. [65]Prochownik E.V. C-myc: Linking transformation and genomic instability Curr. Mol. Med. 2008 8 446 458 10.2174/156652408785747988 18781952 · DOI
  64. [66]Ray S. Atkuri K.R. Deb-Basu D. Adler A.S. Chang H.Y. Herzenberg L.A. Felsher D.W. Myc can induce DNA breaks in vivo and in vitro independent of reactive oxygen species Cancer Res. 2006 66 6598 6605 10.1158/0008-5472.CAN-05-3115 16818632 · DOI
  65. [67]Shachaf C.M. Kopelman A.M. Arvanitis C. Karlsson A. Beer S. Mandl S. Bachmann M.H. Borowsky A.D. Ruebner B. Cardiff R.D. Myc inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer Nature 2004 431 1112 1117 10.1038/nature03043 15475948 · DOI · Paper page
  66. [68]Shachaf C.M. Gentles A.J. Elchuri S. Sahoo D. Soen Y. Sharpe O. Perez O.D. Chang M. Mitchel D. Robinson W.H. Genomic and proteomic analysis reveals a threshold level of myc required for tumor maintenance Cancer Res. 2008 68 5132 5142 10.1158/0008-5472.CAN-07-6192 18593912 PMC4191850 · DOI
  67. [69]Dauch D. Rudalska R. Cossa G. Nault J.C. Kang T.W. Wuestefeld T. Hohmeyer A. Imbeaud S. Yevsa T. Hoenicke L. A myc-aurora kinase a protein complex represents an actionable drug target in p53-altered liver cancer Nat. Med. 2016 22 744 753 10.1038/nm.4107 27213815 · DOI
  68. [70]D’Cruz C.M. Gunther E.J. Boxer R.B. Hartman J.L. Sintasath L. Moody S.E. Cox J.D. Ha S.I. Belka G.K. Golant A. C-myc induces mammary tumorigenesis by means of a preferred pathway involving spontaneous kras2 mutations Nat. Med. 2001 7 235 239 10.1038/84691 11175856 · DOI
  69. [71]Amati B. Brooks M.W. Levy N. Littlewood T.D. Evan G.I. Land H. Oncogenic activity of the c-myc protein requires dimerization with max Cell 1993 72 233 245 10.1016/0092-8674(93)90663-B 8425220 · DOI
  70. [72]Amati B. Dalton S. Brooks M.W. Littlewood T.D. Evan G.I. Land H. Transcriptional activation by the human c-myc oncoprotein in yeast requires interaction with max Nature 1992 359 423 426 10.1038/359423a0 1406955 · DOI
  71. [73]Blackwood E.M. Eisenman R.N. Max: A helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with myc Science 1991 251 1211 1217 10.1126/science.2006410 2006410 · DOI
  72. [74]Grinberg A.V. Hu C.D. Kerppola T.K. Visualization of myc/max/mad family dimers and the competition for dimerization in living cells Mol. Cell. Biol. 2004 24 4294 4308 10.1128/MCB.24.10.4294-4308.2004 15121849 PMC400484 · DOI
  73. [75]Kato G.J. Lee W.M. Chen L.L. Dang C.V. Max: Functional domains and interaction with c-myc Genes Dev. 1992 6 81 92 10.1101/gad.6.1.81 1730412 · DOI
  74. [76]Kretzner L. Blackwood E.M. Eisenman R.N. Myc and max proteins possess distinct transcriptional activities Nature 1992 359 426 429 10.1038/359426a0 1406956 · DOI
  75. [77]Hopewell R. Ziff E.B. The nerve growth factor-responsive pc12 cell line does not express the myc dimerization partner max Mol. Cell. Biol. 1995 15 3470 3478 10.1128/MCB.15.7.3470 7791753 PMC230583 · DOI
  76. [78]Steiger D. Furrer M. Schwinkendorf D. Gallant P. Max-independent functions of myc in drosophila melanogaster Nat. Genet. 2008 40 1084 1091 10.1038/ng.178 19165923 · DOI
  77. [79]Lin C.P. Liu J.D. Chow J.M. Liu C.R. Liu H.E. Small-molecule c-myc inhibitor, 10058-f4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells Anticancer Drugs 2007 18 161 170 10.1097/CAD.0b013e3280109424 17159602 · DOI
  78. [80]Guo J. Parise R.A. Joseph E. Egorin M.J. Lazo J.S. Prochownik E.V. Eiseman J.L. Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the myc-max disruptor, 10058-f4 [z,e]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice Cancer Chemother. Pharmacol. 2009 63 615 625 10.1007/s00280-008-0774-y 18509642 PMC2752825 · DOI
  79. [81]Wang H. Hammoudeh D.I. Follis A.V. Reese B.E. Lazo J.S. Metallo S.J. Prochownik E.V. Improved low molecular weight myc-max inhibitors Mol. Cancer Ther. 2007 6 2399 2408 10.1158/1535-7163.MCT-07-0005 17876039 · DOI
  80. [82]Brooks T.A. Hurley L.H. Targeting myc expression through g-quadruplexes Genes Cancer 2010 1 641 649 10.1177/1947601910377493 21113409 PMC2992328 · DOI
  81. [83]Porporato P.E. Dhup S. Dadhich R.K. Copetti T. Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: A comprehensive review Front. Pharmacol. 2011 2 49 10.3389/fphar.2011.00049 21904528 PMC3161244 · DOI
  82. [84]Chang T.C. Yu D. Lee Y.S. Wentzel E.A. Arking D.E. West K.M. Dang C.V. Thomas-Tikhonenko A. Mendell J.T. Widespread microrna repression by myc contributes to tumorigenesis Nat. Genet. 2008 40 43 50 10.1038/ng.2007.30 18066065 PMC2628762 · DOI
  83. [85]O’Donnell K.A. Wentzel E.A. Zeller K.I. Dang C.V. Mendell J.T. C-myc-regulated micrornas modulate e2f1 expression Nature 2005 435 839 843 10.1038/nature03677 15944709 · DOI
  84. [86]Kato M. Slack F.J. Micrornas: Small molecules with big roles—c. Elegans to human cancer Biol. Cell 2008 100 71 81 10.1042/BC20070078 18199046 · DOI
  85. [87]Kota J. Chivukula R.R. O’Donnell K.A. Wentzel E.A. Montgomery C.L. Hwang H.W. Chang T.C. Vivekanandan P. Torbenson M. Clark K.R. Therapeutic microrna delivery suppresses tumorigenesis in a murine liver cancer model Cell 2009 137 1005 1017 10.1016/j.cell.2009.04.021 19524505 PMC2722880 · DOI
  86. [88]Tao J. Ji J. Li X. Ding N. Wu H. Liu Y. Wang X.W. Calvisi D.F. Song G. Chen X. Distinct anti-oncogenic effect of various micrornas in different mouse models of liver cancer Oncotarget 2015 6 6977 6988 10.18632/oncotarget.3166 25762642 PMC4466663 · DOI
  87. [89]Schreiber S.L. Bernstein B.E. Signaling network model of chromatin Cell 2002 111 771 778 10.1016/S0092-8674(02)01196-0 12526804 · DOI
  88. [90]Rahman S. Sowa M.E. Ottinger M. Smith J.A. Shi Y. Harper J.W. Howley P.M. The brd4 extraterminal domain confers transcription activation independent of ptefb by recruiting multiple proteins, including nsd3 Mol. Cell. Biol. 2011 31 2641 2652 10.1128/MCB.01341-10 21555454 PMC3133372 · DOI · Paper page
  89. [91]Delmore J.E. Issa G.C. Lemieux M.E. Rahl P.B. Shi J. Jacobs H.M. Kastritis E. Gilpatrick T. Paranal R.M. Qi J. Bet bromodomain inhibition as a therapeutic strategy to target c-myc Cell 2011 146 904 917 10.1016/j.cell.2011.08.017 21889194 PMC3187920 · DOI
  90. [92]Browning J.D. Horton J.D. Molecular mediators of hepatic steatosis and liver injury J. Clin. Investig. 2004 114 147 152 10.1172/JCI200422422 15254578 PMC449757 · DOI · Paper page
  91. [93]Friedman S.L. Molecular mechanisms of hepatic fibrosis and principles of therapy J. Gastroenterol. 1997 32 424 430 10.1007/BF02934504 9213261 · DOI
  92. [94]Nevzorova Y.A. Hu W. Cubero F.J. Haas U. Freimuth J. Tacke F. Trautwein C. Liedtke C. Overexpression of c-myc in hepatocytes promotes activation of hepatic stellate cells and facilitates the onset of liver fibrosis Biochim. Biophys. Acta 2013 1832 1765 1775 10.1016/j.bbadis.2013.06.001 23770341 · DOI
  93. [95]Fattovich G. Stroffolini T. Zagni I. Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors Gastroenterology 2004 127 S35 S50 10.1053/j.gastro.2004.09.014 15508101 · DOI
  94. [96]Aiba N. Nambu S. Inoue K. Sasaki H. Hypomethylation of the c-myc oncogene in liver cirrhosis and chronic hepatitis Gastroenterol. Jpn. 1989 24 270 276 2545502
  95. [97]Chung S.I. Moon H. Kim D.Y. Cho K.J. Ju H.L. Kim do Y. Ahn S.H. Han K.H. Ro S.W. Development of a transgenic mouse model of hepatocellular carcinoma with a liver fibrosis background BMC Gastroenterol. 2016 16 13 10.1186/s12876-016-0423-6 26821924 PMC4731926 · DOI
  96. [98]Himeno Y. Fukuda Y. Hatanaka M. Imura H. Expression of oncogenes in human liver disease Liver 1988 8 208 212 10.1111/j.1600-0676.1988.tb00994.x 2843721 · DOI
  97. [99]Balsano C. Avantaggiati M.L. Natoli G. De Marzio E. Will H. Perricaudet M. Levrero M. Full-length and truncated versions of the hepatitis b virus (hbv) x protein (px) transactivate the cmyc protooncogene at the transcriptional level Biochem. Biophys. Res. Commun. 1991 176 985 992 10.1016/0006-291X(91)90379-L 1645550 · DOI
  98. [100]Lakhtakia R. Kumar V. Reddi H. Mathur M. Dattagupta S. Panda S.K. Hepatocellular carcinoma in a hepatitis b ‘x’ transgenic mouse model: A sequential pathological evaluation J. Gastroenterol. Hepatol. 2003 18 80 91 10.1046/j.1440-1746.2003.02902.x 12519229 · DOI
  99. [101]Lee S. Kim W. Ko C. Ryu W.S. Hepatitis b virus x protein enhances myc stability by inhibiting scf (skp2) ubiquitin e3 ligase-mediated myc ubiquitination and contributes to oncogenesis Oncogene 2016 35 1857 1867 10.1038/onc.2015.251 26165841 · DOI
  100. [102]Iizuka N. Tsunedomi R. Tamesa T. Okada T. Sakamoto K. Hamaguchi T. Yamada-Okabe H. Miyamoto T. Uchimura S. Hamamoto Y. Involvement of c-myc-regulated genes in hepatocellular carcinoma related to genotype-c hepatitis b virus J. Cancer Res. Clin. Oncol. 2006 132 473 481 10.1007/s00432-006-0094-8 16703398 PMC12161096 · DOI
  101. [103]Huppi K. Pitt J.J. Wahlberg B.M. Caplen N.J. The 8q24 gene desert: An oasis of non-coding transcriptional activity Front. Genet. 2012 3 69 10.3389/fgene.2012.00069 22558003 PMC3339310 · DOI
  102. [104]Yan H. Yang Y. Zhang L. Tang G. Wang Y. Xue G. Zhou W. Sun S. Characterization of the genotype and integration patterns of hepatitis b virus in early- and late-onset hepatocellular carcinoma Hepatology 2015 61 1821 1831 10.1002/hep.27722 25627239 · DOI
  103. [105]Hung L. Kumar V. Specific inhibition of gene expression and transactivation functions of hepatitis b virus x protein and c-myc by small interfering rnas FEBS Lett. 2004 560 210 214 10.1016/S0014-5793(04)00113-9 14988024 · DOI
  104. [106]Hung L. Kumar V. Antisense regulation of expression and transactivation functions of the tumorigenic hbx and c-myc genes Biochem. Biophys. Res. Commun. 2006 344 293 299 10.1016/j.bbrc.2006.03.103 16616001 · DOI
  105. [107]El-Serag H.B. Hepatocellular carcinoma and hepatitis c in the united states Hepatology 2002 36 S74 S83 10.1002/hep.1840360710 12407579 · DOI
  106. [108]Higgs M.R. Lerat H. Pawlotsky J.M. Hepatitis c virus-induced activation of beta-catenin promotes c-myc expression and a cascade of pro-carcinogenetic events Oncogene 2013 32 4683 4693 10.1038/onc.2012.484 23108410 · DOI
  107. [109]O’Shea R.S. Dasarathy S. McCullough A.J. Alcoholic liver disease Hepatology 2010 51 307 328 10.1002/hep.23258 20034030 · DOI
  108. [110]Gao B. Bataller R. Alcoholic liver disease: Pathogenesis and new therapeutic targets Gastroenterology 2011 141 1572 1585 10.1053/j.gastro.2011.09.002 21920463 PMC3214974 · DOI · Paper page
  109. [111]Testino G. Borro P. Alcohol and gastrointestinal oncology World J. Gastrointest. Oncol. 2010 2 322 325 10.4251/wjgo.v2.i8.322 21160893 PMC2999678 · DOI
  110. [112]Testino G. Borro P. Ancarani O. Sumberaz A. Human carcinogenesis and alcohol in hepato-gastroenterology Eur. Rev. Med. Pharmacol. Sci. 2012 16 512 518 22696879
  111. [113]Testino G. Leone S. Borro P. Alcohol and hepatocellular carcinoma: A review and a point of view World J. Gastroenterol. 2014 20 15943 15954 10.3748/wjg.v20.i43.15943 25473148 PMC4239482 · DOI
  112. [114]Morgan T.R. Mandayam S. Jamal M.M. Alcohol and hepatocellular carcinoma Gastroenterology 2004 127 S87 S96 10.1053/j.gastro.2004.09.020 15508108 · DOI
  113. [115]Day C.P. Bassendine M.F. Genetic predisposition to alcoholic liver disease Gut 1992 33 1444 1447 10.1136/gut.33.11.1444 1452064 PMC1379524 · DOI
  114. [116]Devor E.J. Reich T. Cloninger C.R. Genetics of alcoholism and related end-organ damage Semin. Liver Dis. 1988 8 1 11 10.1055/s-2008-1040524 3283940 · DOI
  115. [117]Goodwin D.W. Genetic influences in alcoholism Adv. Intern. Med. 1987 32 283 297 3548253
  116. [118]Nevzorova Y.A. Cubero F.J. Hu W. Hao F. Haas U. Ramadori P. Gassler N. Hoss M. Strnad P. Zimmermann H.W. Enhanced expression of c-myc in hepatocytes promotes initiation and progression of alcoholic liver disease J. Hepatol. 2016 64 628 640 10.1016/j.jhep.2015.11.005 26576483 · DOI
  117. [119]Buendia M.A. Bourre L. Cairo S. Myc target mirs and liver cancer: Small molecules to get myc sick Gastroenterology 2012 142 214 218 10.1053/j.gastro.2011.12.023 22178210 · DOI
  118. [120]Comerford S.A. Hinnant E.A. Chen Y. Bansal H. Klapproth S. Rakheja D. Finegold M.J. Lopez-Terrada D. O’Donnell K.A. Tomlinson G.E. Hepatoblastoma modeling in mice places nrf2 within a cancer field established by mutant beta-catenin JCI Insight 2016 1 e88549 10.1172/jci.insight.88549 27734029 PMC5053152 · DOI
  119. [121]Cairo S. Armengol C. De Reynies A. Wei Y. Thomas E. Renard C.A. Goga A. Balakrishnan A. Semeraro M. Gresh L. Hepatic stem-like phenotype and interplay of wnt/beta-catenin and myc signaling in aggressive childhood liver cancer Cancer Cell 2008 14 471 484 10.1016/j.ccr.2008.11.002 19061838 · DOI
  120. [122]Cairo S. Wang Y. de Reynies A. Duroure K. Dahan J. Redon M.J. Fabre M. McClelland M. Wang X.W. Croce C.M. Stem cell-like micro-rna signature driven by myc in aggressive liver cancer Proc. Natl. Acad. Sci. USA 2010 107 20471 20476 10.1073/pnas.1009009107 21059911 PMC2996672 · DOI
  121. [123]Yang H. Li T.W. Peng J. Tang X. Ko K.S. Xia M. Aller M.A. A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression Gastroenterology 2011 141 378 388 10.1053/j.gastro.2011.03.044 21440549 PMC3129489 · DOI
  122. [125]Nakamura I. Roberts L.R. Myc, max, and mnt: Molecular mechanisms of enhancement of cholangiocarcinogenesis by cholestasis Gastroenterology 2011 141 32 34 10.1053/j.gastro.2011.05.022 21620848 PMC4040264 · DOI
  123. [126]Yang H. Liu T. Wang J. Li T.W. Fan W. Peng H. Krishnan A. Gores G.J. Mato J.M. Lu S.C. Deregulated methionine adenosyltransferase alpha1, c-myc, and maf proteins together promote cholangiocarcinoma growth in mice and humans(double dagger) Hepatology 2016 64 439 455 10.1002/hep.28541 26969892 PMC4956551 · DOI
  124. [127]Berasain C. Fernandez-Barrena M.G. Avila M.A. New molecular interactions of c-myc in cholangiocarcinoma may open new therapeutic opportunities Hepatology 2016 64 336 339 10.1002/hep.28607 27102840 · DOI
  125. [128]Radziuk J. Pye S. Hepatic glucose uptake, gluconeogenesis and the regulation of glycogen synthesis Diabetes Metab. Res. Rev. 2001 17 250 272 10.1002/dmrr.217 11544610 · DOI · Paper page
  126. [129]Vaulont S. Vasseur-Cognet M. Kahn A. Glucose regulation of gene transcription J. Biol. Chem. 2000 275 31555 31558 10.1074/jbc.R000016200 10934218 · DOI
  127. [130]Valera A. Pujol A. Gregori X. Riu E. Visa J. Bosch F. Evidence from transgenic mice that myc regulates hepatic glycolysis FASEB J. 1995 9 1067 1078 7649406
  128. [131]Riu E. Bosch F. Valera A. Prevention of diabetic alterations in transgenic mice overexpressing myc in the liver Proc. Natl. Acad. Sci. USA 1996 93 2198 2202 10.1073/pnas.93.5.2198 8700908 PMC39934 · DOI
  129. [132]Riu E. Ferre T. Mas A. Hidalgo A. Franckhauser S. Bosch F. Overexpression of c-myc in diabetic mice restores altered expression of the transcription factor genes that regulate liver metabolism Biochem. J. 2002 368 931 937 10.1042/bj20020605 12230428 PMC1223040 · DOI
  130. [133]Riu E. Ferre T. Hidalgo A. Mas A. Franckhauser S. Otaegui P. Bosch F. Overexpression of c-myc in the liver prevents obesity and insulin resistance FASEB J. 2003 17 1715 1717 10.1096/fj.02-1163fje 12958186 · DOI
  131. [134]Hermeking H. Rago C. Schuhmacher M. Li Q. Barrett J.F. Obaya A.J. O’Connell B.C. Mateyak M.K. Tam W. Kohlhuber F. Identification of cdk4 as a target of c-myc Proc. Natl. Acad. Sci. USA 2000 97 2229 2234 10.1073/pnas.050586197 10688915 PMC15783 · DOI
  132. [135]Orian A. van Steensel B. Delrow J. Bussemaker H.J. Li L. Sawado T. Williams E. Loo L.W. Cowley S.M. Yost C. Genomic binding by the drosophila myc, max, mad/mnt transcription factor network Genes Dev. 2003 17 1101 1114 10.1101/gad.1066903 12695332 PMC196053 · DOI

Cited by

Sorted by citations

Authors
Zheng, K., Cubero, F., & Nevzorova, Y.
Affiliations
Universidad Complutense de Madrid (ES)
Corresponding author
  • Cubero, Francisco
  • Nevzorova, Yulia
ORCID
Venue
Genes
Publisher
MDPI AG
Published
2017-04-19
Volume
8
Issue
4
Pages
123
ISSN
2073-4425 (ISSN-L)
DOI
10.3390/genes8040123
PMC
PMC5406870
OpenAlex
W2605477612
Cited by
84
References
3
Citations by year
2026: 4 · 2025: 9 · 2024: 8 · 2023: 12 · 2022: 16 · 2021: 10 · 2020: 4 · 2019: 12 · 2018: 7 · 2017: 2
FWCI
0.99
Type
journal article
Language
en
Open access
Licence
Locations
  • Genes (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (acceptedVersion)
  • RWTH Publications (RWTH Aachen) (submittedVersion, cc-by)
  • Library Open Repository (Universidad Complutense Madrid) (submittedVersion, cc-by)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • RWTH Publications (RWTH Aachen)
Funders
  • Ramón y Cajal Researchers (RyC2014-15242)
  • Chinese Scholarship Council
  • German Research Foundation (DFG NE 2128/2-1, SFB/TRR57/P04)
  • Ramón y Cajal Research (RYC2015-17438)
  • Spanish Ministerio de Economía y Competitividad (SAF2016-78711)
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Keywords
c-Myc, liver, liver homeostasis, liver disease, transcription factors, cell proliferation, cell cycle, cellular metabolism, DNA replication, cell adhesion, cell differentiation, MYC overexpression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review